Intensifying competition driven by the growing adoption of balloon catheters for cryoablation
First written in FY2018-Q2. 12 of 13 entries say "Restated". Latest entry: FY2025-H1.
No other company in this theme has enough history to compare yet.
- FY2025-H1RestatedAnnual report
「No new business or other risks arose during the current interim consolidated accounting period. In addition, there were no material changes to the business and other risks described in the securities report for the previous fiscal year.」
The Company has disclosed that there has been no material change regarding the risk of intensifying competition due to the growing adoption of balloon catheters for cryoablation. - FY2024-Q3RestatedAnnual report
「No new business or other risks arose during the cumulative third quarter of the current consolidated fiscal year. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
The Company has disclosed that there has been no material change regarding the risk of intensifying competition due to the growing adoption of balloon catheters for cryoablation. - FY2021-Q2RestatedAnnual report
「No new business or other risks arose during the six-month period ended [the second quarter]. There were also no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The Company has disclosed that there has been no material change regarding the risk of intensifying competition due to the growing adoption of balloon catheters for cryoablation. - FY2020-Q3RestatedAnnual report
「This product enables precise treatment tailored to each case while allowing the ablation site to be viewed with an endoscope, and we will work to achieve its further adoption in clinical practice.」
Against the backdrop of the growing adoption of balloon technology-based treatment, the Company continues efforts to achieve the further adoption of HeartLight in clinical practice. - FY2020-Q2RestatedAnnual report
「By combining an endoscope and a laser, this product enables precise treatment tailored to each case, and we are continuing efforts to achieve its broader adoption in clinical practice.」
The Company continues efforts to establish HeartLight in clinical practice in response to the growing adoption of balloon technology-based treatment. - FY2020-Q1RestatedAnnual report
「Meanwhile, we are working to establish the endoscopic laser ablation catheter HeartLight in clinical practice, as its combination of an endoscope and laser enables precise treatment tailored to each case.」
The Company continues efforts to establish HeartLight in clinical practice in response to the growing adoption of balloon technology-based treatment. - FY2019RestatedAnnual report
「Balloon technology-based ablation treatment for atrial fibrillation is expected to simplify procedures and see further adoption going forward.」
The Company continues to pursue its policy of establishing HeartLight in clinical practice, in light of the outlook for the growing adoption of balloon technology-based treatment. - FY2019-Q3RestatedAnnual report
「As balloon technology-based ablation treatment for atrial fibrillation is expected to become even more widely adopted, we will continue working to establish this product in clinical practice.」
In light of the outlook for the growing adoption of balloon technology-based treatment, the Company has stated its policy of continuing efforts to establish HeartLight in clinical practice. - FY2019-Q2RestatedAnnual report
「As balloon technology-based ablation catheters have become more widely adopted in the treatment of atrial fibrillation in recent years, we will work to achieve the early penetration of this product.」
The Company has reiterated its policy of seeking the early penetration of HeartLight amid the continued adoption of competing and new-generation balloon technology. - FY2019-Q1RestatedAnnual report
「Ablation catheter sales volume declined from the same period of the previous year due to the growing adoption of balloon catheters for cryoablation and other products sold by competitors.」
The continued adoption of competitors' balloon catheters for cryoablation and other products has been a factor in the decline in ablation catheter sales volume. - FY2018RestatedAnnual report
「Revenue from ablation catheters declined from the previous fiscal year, reflecting factors including the growing adoption of balloon catheters for cryoablation sold by competitors.」
The decline in revenue due to the growing adoption of competitors' balloon catheters for cryoablation has continued. - FY2018-Q3RestatedAnnual report
「Revenue from ablation catheters declined from the same period of the previous year, reflecting factors including the growing adoption of balloon catheters for cryoablation sold by competitors.」
The impact on sales from the growing adoption of competitors' balloon catheters for cryoablation has continued. - FY2018-Q2First statedAnnual report
「Meanwhile, sales volume of ablation catheters declined from the same period of the previous year, reflecting factors including the growing adoption of balloon catheters for cryoablation sold by competitors.」
The growing adoption of competitors' balloon catheters for cryoablation was reflected in a year-on-year decline in ablation catheter sales volume.